Kite catches the inside track on the last leg of a race to the finish line with Novartis on a CAR-T first
The race between Novartis $NVS and Kite $KITE to win the first FDA approval of a CAR-T for cancer is now in the final stretch, and Kite just shortened its distance to the finish line.
The biotech announced this morning that the FDA is providing a priority review for their drug KTE-C19 (axicabtagene ciloleucel), which will cut the time it takes for regulators to complete their examination from 10 months down to 6. The FDA’s PDUFA date is November 29.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.